US › Healthcare

Organogenesis Holdings Inc (ORGO)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$1.36-2.16%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$43.8M

Revenue YoY

-56.6%

Net profit

$-99.3M

EPS

$-0.71

EPS estimate

$-0.35

Net margin

-227.0%

EPS came in at -0.71 against a street estimate of -0.35 — a miss of 102.9%.

Key statistics

Market cap

$196.9M

Forward P/E

12.7

P/B

1.37

Book value

$1.15

EPS (TTM)

$-0.79

52-week high

$7.08

52-week low

$1.49

50-day MA

$2.13

200-day MA

$3.06

Beta

1.29

Analyst view

Analysts rate Organogenesis Holdings Inc a strong buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $2.00.

Shareholding

Insiders

47.46%

Institutions

51.81%

Largest institutional holders

Fund	Stake
Morgan Stanley - Brokerage Accounts	9.03%
Soleus Capital Management, L.P.	7.88%
BlackRock Inc	3.81%
Dimensional Fund Advisors, Inc.	2.37%
Vanguard Capital Management, LLC	2.25%
D. E. Shaw & Co LP	2.24%
Assenagon Asset Management SA	1.53%
Geode Capital Management, LLC	1.39%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Organogenesis Holdings Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.